CYP2C9

Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population

M. Zhang, Yang, Y., Zhao, G., Di, X., Xu, L., Jiang, N., Xu, J., and Xu, X., Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population, vol. 13, pp. 831-837, 2014.

The aim of this study was to investigate the effect of the CYP2C9*3 (CYP2C9 1075 A>C) polymorphism on meloxicam pharmacokinetics in a Chinese population. Twenty-four healthy volunteers were enrolled in this study. The pyrosequencing technique was used to identify polymorphisms of CYP2C9. The concentration of meloxicam in plasma was determined by a high-performance liquid chromatography assay with mass spectrographic analysis. The Drug and Statistics Software (DAS, version 2.0) was used for curve fitting and calculations of pharmacokinetic parameters.

Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants

P. Scibona, Redal, M. A., Garfi, L. G., Arbelbide, J., Argibay, P. F., and Belloso, W. H., Prevalence of CYP2C9 and VKORC1 alleles in the Argentine population and implications for prescribing dosages of anticoagulants, vol. 11, pp. 70-76, 2012.

Dicumarinic oral anticoagulants have a narrow therapeutic range and a great individual variability in response, which makes calculation of the correct dose difficult and critical. Genetic factors involved in this variability include polymorphisms of genes that encode the metabolic enzyme CYP2C9 and the target enzyme vitamin K epoxide reductase complex 1 (VKORC1); these polymorphisms can be associated with reduced enzymatic expression.

Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response

J. A. Nastasi-Catanese, Padilla-Gutiérrez, J. R., Valle, Y., Ortega-Gutiérrez, F., Gallegos-Arreola, M. P., and Figuera, L. E., Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response, vol. 12, pp. 4413-4421, 2013.

Oral anticoagulants of the coumarin type have an inconveniently narrow therapeutic window, making their use difficult. In Mexico, genetic variables that participate in the heterogeneity of the therapeutic response remain poorly investigated. With the focus on warfarin, extensive pharmacogenomic studies have been performed, including those on the CYP450 family and APOE.

Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China

Z. F. Yang, Cui, H. W., Hasi, T., Jia, S. Q., Gong, M. L., and Su, X. L., Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China, vol. 9, pp. 1844-1851, 2010.

We examined the distribution of major allelic variants of CYP2C9 and CYP2C19 in the Mongolian population of China and compared it with that of other populations. The polymorphisms of CYP2C9 (including the CYP2C9*1, CYP2C9*2 and CYP2C9*3 alleles) and CYP2C19 (including the CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles) were analyzed in 280 healthy unrelated Chinese Mongolian subjects, using a PCR-RFLP assay.

Subscribe to CYP2C9